CONMED Corporation
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B | 5.2% | |
| Cost of Revenue | (442.60M) | (474.23M) | (568.50M) | (573.98M) | (649.12M) | 13.1% | |
Gross Profit | 568.04M | 571.25M | 676.25M | 733.03M | 725.38M | -1.0% | |
| Operating Expenses | |||||||
| Research & Development | (43.56M) | (47.15M) | (52.60M) | (54.43M) | (55.88M) | 2.7% | |
| Selling, General & Administrative | (414.75M) | (454.04M) | (503.04M) | (478.28M) | (528.36M) | 10.5% | |
| Depreciation & Amortization | (70.74M) | (49.76M) | (71.87M) | (71.86M) | (52.34M) | -27.2% | |
Operating Income (EBIT) | 109.72M | 70.05M | 120.60M | 200.33M | 141.13M | -29.5% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | — | — | |
| Interest Expense | (35.48M) | (28.91M) | (39.77M) | (37.30M) | (31.09M) | -16.7% | |
| Other Income/Expenses (Net) | -36.61M | -140.92M | -39.77M | -37.30M | -70.01M | 87.7% | |
Income Before Tax | 73.11M | -70.86M | 80.83M | 163.03M | 71.12M | -56.4% | |
| Income Tax Expense | (10.56M) | (9.72M) | (16.37M) | (30.61M) | (24.06M) | -21.4% | |
Net Income | 62.54M | -80.58M | 64.46M | 132.42M | 47.05M | -64.5% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $-3 | $2 | $4 | $2 | -64.6% | |
| Weighted Avg Shares Outstanding | 29.16M | 30.04M | 30.67M | 30.85M | 31.04M | 0.6% | |
| Weighted Avg Shares Outstanding (Diluted) | 32.22M | 30.04M | 31.55M | 31.11M | 31.15M | 0.1% | |
EBITDA | 179.33M | 7.80M | 192.48M | 272.18M | 154.55M | -43.2% |
Explore CNMD
CNMD in the Healthcare
Small Cap